Particle-based vaccines for transcutaneous vaccination

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 31, Issue 2-3, 2008, Pages 293-315

  Combadière, Behazine ^a   Mahé, Brice ^a  

^a INSERM   (France)

Author keywords

Immune responses; Nanoparticles; Skin; Vaccination

Indexed keywords

CHITOSAN; CHOLERA TOXIN; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; ISCOM; LIPOSOME; LIVE VACCINE; MALARIA VACCINE; MEASLES VACCINE; MICROSPHERE; NANOPARTICLE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; POLYGLACTIN; POLYLACTIDE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; ROTAVIRUS VACCINE; VACCINE; VIROSOME;

ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CHOLERA; DENDRITIC CELL; DERMIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; ELECTROPORATION; ENCAPSULATION; EPIDERMIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; MALARIA; MEASLES; NONHUMAN; PARTICLE SIZE; PERTUSSIS; POLIOMYELITIS; SKIN; SKIN PERMEABILITY; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; HUMANS; NANOPARTICLES; SKIN; VACCINES;

ANIMALIA;

EID: 39849085505     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cimid.2007.07.015     Document Type: Article

References (169)

1. Raz E., Carson D.A., Parker S.E., Parr T.B., Abai A.M., Aichinger G., et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 91 20 (1994) 9519-9523
2. Iwasaki A., Stiernholm B.J., Chan A.K., Berinstein N.L., and Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 158 10 (1997) 4591-4601
3. Stan A.C., Casares S., Brumeanu T.D., Klinman D.M., and Bona C.A. CpG motifs of DNA vaccines induce the expression of chemokines and MHC Class II molecules on myocytes. Eur J Immunol 31 1 (2001) 301-310
4. Torres C.A., Iwasaki A., Barber B.H., and Robinson H.L. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol 158 10 (1997) 4529-4532
5. Barouch D.H., Santra S., Tenner-Racz K., Racz P., Kuroda M.J., Schmitz J.E., et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 168 2 (2002) 562-568
6. Sumida S.M., McKay P.F., Truitt D.M., Kishko M.G., Arthur J.C., Seaman M.S., et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 114 9 (2004) 1334-1342
7. Bos J.D., and Kapsenberg M.L. The skin immune system: progress in cutaneous biology. Immunol Today 14 2 (1993) 75-78
8. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245-252
9. Kupper T.S., and Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 4 3 (2004) 211-222
10. Charest A.F., McDougall J., and Goldstein M.B. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 36 5 (2000) 976-982
11. Egemen A., Aksit S., Kurugol Z., Erensoy S., Bilgic A., and Akilli M. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children. Vaccine 16 16 (1998) 1511-1515
12. Sabchareon A., Chantavanich P., Pasuralertsakul S., Pojjaroen-Anant C., Prarinyanupharb V., Attanath P., et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatric Infect Dis J 17 11 (1998) 1001-1007
13. Streilein J.W., Taylor J.R., Vincek V., Kurimoto I., Shimizu T., Tie C., et al. Immune surveillance and sunlight-induced skin cancer. Immunol Today 15 4 (1994) 174-179
14. Sallusto F. Origin and migratory properties of dendritic cells in the skin. Curr Opin Allergy Clin Immunol 1 5 (2001) 441-448
15. Vogt A., Combadiere B., Hadam S., Stieler K.M., Lademann J., Schaefer H., et al. 40 nm, But not 750 or 1500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol 126 6 (2006) 1316-1322
16. Lenz A., Heine M., Schuler G., and Romani N. Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 92 6 (1993) 2587-2596
17. Romani N., Lenz A., Glassel H., Stossel H., Stanzl U., Majdic O., et al. Cultured human Langerhans cells resemble lymphoid dendritic cells in phenotype and function. J Invest Dermatol 93 (1989) 600-609
18. Itano A.A., McSorley S.J., Reinhardt R.L., Ehst B.D., Ingulli E., Rudensky A.Y., et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19 1 (2003) 47-57
19. Wilson H.L., and O'Neill H.C. Identification of differentially expressed genes representing dendritic cell precursors and their progeny. Blood 102 5 (2003) 1661-1669
20. Wilson N.S., El-Sukkari D., Belz G.T., Smith C.M., Steptoe R.J., Heath W.R., et al. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 102 6 (2003) 2187-2194
21. Valladeau J., Ravel O., Dezutter-Dambuyant C., Moore K., Kleijmeer M., Liu Y., et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12 1 (2000) 71-81
22. Larregina A.T., Morelli A.E., Spencer L.A., Logar A.J., Watkins S.C., Thomson A.W., et al. Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol 2 12 (2001) 1151-1158
23. Merad M., Manz M.G., Karsunky H., Wagers A., Peters W., Charo I., et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 3 12 (2002) 1135-1141
24. Dieu M.C., Vanbervliet B., Vicari A., Bridon J.M., Oldham E., Ait-Yahia S., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188 2 (1998) 373-386
25. Caux C., Ait-Yahia S., Chemin K., de Bouteiller O., Dieu-Nosjean M.C., Homey B., et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 22 4 (2000) 345-369
26. Sallusto F., Palermo B., Lenig D., Miettinen M., Matikainen S., Julkunen I., et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 29 5 (1999) 1617-1625
27. Sozzani S., Allavena P., Vecchi A., and Mantovani A. Chemokines and dendritic cell traffic. J Clin Immunol 20 3 (2000) 151-160
28. Mayerova D., Wang L., Bursch L.S., and Hogquist K.A. Conditioning of Langerhans cells induced by a primary CD8 T cell response to self-antigen in vivo. J Immunol 176 8 (2006) 4658-4665
29. Mayerova D., Parke E.A., Bursch L.S., Odumade O.A., and Hogquist K.A. Langerhans cells activate naive self-antigen-specific CD8 T cells in the steady state. Immunity 21 3 (2004) 391-400
30. Merad M., Hoffmann P., Ranheim E., Slaymaker S., Manz M.G., Lira S.A., et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 10 5 (2004) 510-517
31. Merad M., Hoffmann P., Ranheim E., Slaymaker S., Manz M.G., Lira S.A., et al. Erratum: depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 10 6 (2004) 649
32. Wang Q., Liu Y., Wang J., Ding G., Zhang W., Chen G., et al. Induction of allospecific tolerance by immature dendritic cells genetically modified to express soluble TNF receptor. J Immunol 177 4 (2006) 2175-2185
33. Probst H.C., McCoy K., Okazaki T., Honjo T., and van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 6 3 (2005) 280-286
34. Probst H.C., Lagnel J., Kollias G., and van den Broek M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity 18 5 (2003) 713-720
35. Abadie V., Badell E., Douillard P., Ensergueix D., Leenen P.J., Tanguy M., et al. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 106 5 (2005) 1843-1850
36. Kupper T.S. Immune and inflammatory processes in cutaneous tissues: mechanisms and speculations. J Clin Invest 86 (1990) 1783-1789
37. Kimber I., Holliday M.R., and Dearman R.J. Cytokine regulation of chemical sensitization. Toxicol Lett 82-83 (1995) 491-496
38. Lukas M., Stossel H., Hefel L., Imamura S., Fritsch P., Sepp N.T., et al. Human cutaneous dendritic cells migrate through dermal lymphatic vessels in a skin organ culture model. J Invest Dermatol 106 6 (1996) 1293-1299
39. Ozawa H., Nakagawa S., Tagami H., and Aiba S. Interleukin-1 beta and granulocyte-macrophage colony-stimulating factor mediate Langerhans cell maturation differently. J Invest Dermatol 106 3 (1996) 441-445
40. Cumberbatch M., Dearman R.J., and Kimber I. Interleukin 1 beta and the stimulation of Langerhans cell migration: comparisons with tumour necrosis factor alpha. Arch Dermatol Res 289 5 (1997) 277-284
41. Cumberbatch M., Dearman R.J., and Kimber I. Constitutive and inducible expression of interleukin-6 by Langerhans cells and lymph node dendritic cells. Immunology 87 4 (1996) 513-518
42. Silberberg-Sinakin I., Thorbecke G.J., Baer R., Rosenthal S.A., and Berezowsky V. Antigen-bearing Langerhans cells in skin, dermal lymphatics and in lymph nodes. Cell Immunol 25 (1976) 137-151
43. Knight S.C., Bedford P., and Hunt R. The role of dendritic cells in the initiation of immune responses to contact sensitzers. II. Studies in nude mice. Cell Immunol 94 (1985) 435-439
44. Larsen C.P., Steinman R.M., Witmer P.M., Hankins D.F., Morris P.J., and Austyn J.M. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 172 5 (1990) 1483-1493
45. Schwarzenberger K., and Udey M.C. Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ. J Invest Dermatol 106 3 (1996) 553-558
46. Saeki H., Moore A.M., Brown M.J., and Hwang S.T. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 162 5 (1999) 2472-2475
47. Nestle F.O., Zheng X.G., Thompson C.B., Turka L.A., and Nickoloff B.J. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol 151 11 (1993) 6535-6545
48. Kaech S.M., Wherry E.J., and Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2 4 (2002) 251-262
49. Robert C., and Kupper T.S. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 341 24 (1999) 1817-1828
50. Humphreys T.L., Baldridge L.A., Billings S.D., Campbell J.J., and Spinola S.M. Trafficking pathways and characterization of CD4 and CD8 cells recruited to the skin of humans experimentally infected with Haemophilus ducreyi. Infect Immun 73 7 (2005) 3896-3902
51. Stingl G., and Steiner G. Immunological host defense of the skin. Curr Probl Dermatol 18 (1989) 22-30
52. Stingl G., Tschachler E., Groh V., Wolff K., and Hauser C. The immune functions of epidermal cells. Immunol Ser 46 (1989) 3-72
53. Bos J.D., and Meinardi M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 9 3 (2000) 165-169
54. Schaefer H., Stuttgen G., Zesch A., Schalla W., and Gazith J. Quantitative determination of percutaneous absorption of radiolabeled drugs in vitro and in vivo by human skin. Curr Probl Dermatol 7 (1978) 80-94
55. Vogt A., Mandt N., Lademann J., Schaefer H., and Blume-Peytavi U. Follicular targeting-a promising tool in selective dermatotherapy. J Invest Dermatol Symp Proc 10 3 (2005) 252-255
56. Schaefer H., and Lademann J. The role of follicular penetration. A differential view. Skin Pharmacol Appl Skin Physiol 14 Suppl. 1 (2001) 23-27
57. Lademann J., Otberg N., Richter H., Weigmann H.J., Lindemann U., Schaefer H., et al. Investigation of follicular penetration of topically applied substances. Skin Pharmacol Appl Skin Physiol 14 Suppl. 1 (2001) 17-22
58. Glenn G.M., Rao M., Matyas G.R., and Alving C.R. Skin immunization made possible by cholera toxin. Nature 391 6670 (1998) 851
59. Glenn G.M., Scharton-Kersten T., Vassell R., Mallett C.P., Hale T.L., and Alving C.R. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 161 7 (1998) 3211-3214
60. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., and Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 6 12 (2000) 1403-1406
61. Frech S.A., Kenney R.T., Spyr C.A., Lazar H., Viret J.F., Herzog C., et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 23 7 (2005) 946-950
62. Peachman K.K., Rao M., and Alving C.R. Immunization with DNA through the skin. Methods 31 3 (2003) 232-242
63. Prausnitz M.R., Edelman E.R., Gimm J.A., Langer R., and Weaver J.C. Transdermal delivery of heparin by skin electroporation. Bio/technology (Nature Publishing Company) 13 11 (1995) 1205-1209
64. Vanbever R., LeBoulenge E., and Preat V. Transdermal delivery of fentanyl by electroporation. I. Influence of electrical factors. Pharm Res 13 4 (1996) 559-565
65. Vanbever R., Morre N.D., and Preat V. Transdermal delivery of fentanyl by electroporation. II. Mechanisms involved in drug transport. Pharm Res 13 9 (1996) 1360-1366
66. Misra A., Ganga S., and Upadhyay P. Needle-free, non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatitis B virus. Vaccine 18 5-6 (1999) 517-523
67. Regnier V., Le Doan T., and Preat V. Parameters controlling topical delivery of oligonucleotides by electroporation. J Drug Targeting 5 4 (1998) 275-289
68. Regnier V., and Preat V. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm Res 15 10 (1998) 1596-1602
69. Bramson J., Dayball K., Evelegh C., Wan Y.H., Page D., and Smith A. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther 10 3 (2003) 251-260
70. Matyas G.R., Friedlander A.M., Glenn G.M., Little S., Yu J., and Alving C.R. Needle-free skin patch vaccination method for anthrax. Infect Immun 72 2 (2004) 1181-1183
71. Eyles J.E., Elvin S.J., Westwood A., Lebutt C.S., Alpar H.O., Somavarapu S., et al. Immunisation against plague by transcutaneous and intradermal application of subunit antigens. Vaccine 22 31-32 (2004) 4365-4373
72. Shi Z., Zeng M., Yang G., Siegel F., Cain L.J., van Kampen K.R., et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol 75 23 (2001) 11474-11482
73. Berry L.J., Hickey D.K., Skelding K.A., Bao S., Rendina A.M., Hansbro P.M., et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 72 2 (2004) 1019-1028
74. Yu J., Cassels F., Scharton-Kersten T., Hammond S.A., Hartman A., Angov E., et al. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun 70 3 (2002) 1056-1068
75. Belyakov I.M., Hammond S.A., Ahlers J.D., Glenn G.M., and Berzofsky J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113 7 (2004) 998-1007
76. Godefroy S., Peyre M., Garcia N., Muller S., Sesardic D., and Partidos C.D. Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM(197), of diphtheria toxin. Infect Immun 73 8 (2005) 4803-4809
77. Watabe S., Xin K.Q., Ihata A., Liu L.J., Honsho A., Aoki I., et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19 31 (2001) 4434-4444
78. El-Ghorr A.A., Williams R.M., Heap C., and Norval M. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice. FEMS Immunol Med Microbiol 29 4 (2000) 255-261
79. Seo N., Tokura Y., Nishijima T., Hashizume H., Furukawa F., and Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci USA 97 1 (2000) 371-376
80. Arlen P.M., Kaufman H.L., and DiPaola R.S. Pox viral vaccine approaches. Semin Oncol 32 6 (2005) 549-555
81. Moll H. Antigen delivery by dendritic cells. Int J Med Microbiol 294 5 (2004) 337-344
82. Liu M., Acres B., Balloul J.M., Bizouarne N., Paul S., Slos P., et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101 Suppl. 2 (2004) 14567-14571
83. Hilleman M.R. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 18 15 (2000) 1436-1447
84. O'Hagan D.T., Singh M., Dong C., Ugozzoli M., Berger K., Glazer E., et al. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23 5 (2004) 672-680
85. O'Hagan D.T., and Rappuoli R. Novel approaches to vaccine delivery. Pharm Res 21 9 (2004) 1519-1530
86. O'Hagan D.T., Singh M., and Ulmer J.B. Microparticles for the delivery of DNA vaccines. Immunol Rev 199 (2004) 191-200
87. Kanke M., Sniecinski I., and DeLuca P.P. Interaction of microspheres with blood constituents: I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. J Parenteral Sci Technol 37 6 (1983) 210-217
88. Tabata Y., and Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9 4 (1988) 356-362
89. Foged C., Brodin B., Frokjaer S., and Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 298 2 (2005) 315-322
90. Florence A.T. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 14 3 (1997) 259-266
91. Lademann J., Richter H., Schaefer U.F., Blume-Peytavi U., Teichmann A., Otberg N., et al. Hair follicles-a long-term reservoir for drug delivery. Skin Pharmacol Physiol 19 4 (2006) 232-236
92. Lademann J., Ilgevicius A., Zurbau O., Liess H.D., Schanzer S., Weigmann H.J., et al. Penetration studies of topically applied substances: optical determination of the amount of stratum corneum removed by tape stripping. J Biomed Opt 11 5 (2006) 054026
93. Cappel M.J., and Kreuter J. Effect of nanoparticles on transdermal drug delivery. J Microencapsulation 8 3 (1991) 369-374
94. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., and Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 112 1 (2006) 26-34
95. Moghimi S.M., Hawley A.E., Christy N.M., Gray T., Illum L., and Davis S.S. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett 344 1 (1994) 25-30
96. Hawley A.E., Illum L., and Davis S.S. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res 14 5 (1997) 657-661
97. Hawley A.E., Illum L., and Davis S.S. Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block co-polymers. FEBS Lett 400 3 (1997) 319-323
98. Strand S.E., and Bergqvist L. Radiolabeled colloids and macromolecules in the lymphatic system. Crit Rev Therap Drug Carrier Systems 6 3 (1989) 211-238
99. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173 5 (2004) 3148-3154
100. Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., and Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 82 5 (2004) 506-516
101. Hueber F., Schaefer H., and Wepierre J. Role of transepidermal and transfollicular routes in percutaneous absorption of steroids: in vitro studies on human skin. Skin Pharmacol 7 5 (1994) 237-244
102. Mottram P.L., Leong D., Crimeen-Irwin B., Gloster S., Xiang S.D., Meanger J., et al. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 4 1 (2007) 73-84
103. Schulz O., and Reis e Sousa C. Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells. Immunology 107 2 (2002) 183-189
104. Langer R., Cleland J.L., and Hanes J. New advances in microsphere-based single-dose vaccines. Adv Drug Deliv Rev 28 1 (1997) 97-119
105. Gupta R.K., Alroy J., Alonso M.J., Langer R., and Siber G.R. Chronic local tissue reactions, long-term immunogenicity and immunologic priming of mice and guinea pigs to tetanus toxoid encapsulated in biodegradable polymer microspheres composed of poly lactide-co-glycolide polymers. Vaccine 15 16 (1997) 1716-1723
106. Hedley M.L., Curley J., and Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 4 3 (1998) 365-368
107. Denis-Mize K.S., Dupuis M., MacKichan M.L., Singh M., Doe B., O'Hagan D., et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 7 24 (2000) 2105-2112
108. Reddy S.T., Swartz M.A., and Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 27 12 (2006) 573-579
109. Lamalle-Bernard D., Munier S., Compagnon C., Charles M.H., Kalyanaraman V.S., Delair T., et al. Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity. J Control Release 115 1 (2006) 57-67
110. Ataman-Onal Y., Munier S., Ganee A., Terrat C., Durand P.Y., Battail N., et al. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J Control Release 112 2 (2006) 175-185
111. Munier S., Messai I., Delair T., Verrier B., and Ataman-Onal Y. Cationic PLA nanoparticles for DNA delivery: comparison of three surface polycations for DNA binding, protection and transfection properties. Colloids Surf 43 3-4 (2005) 163-173
112. Panyam J., and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55 3 (2003) 329-347
113. Jiang G., Joshi S.B., Peek L.J., Brandau D.T., Huang J., Ferriter M.S., et al. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 95 1 (2006) 80-96
114. Audran R., Peter K., Dannull J., Men Y., Scandella E., Groettrup M., et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC Class-I presentation by dendritic cells and macrophages in vitro. Vaccine 21 11-12 (2003) 1250-1255
115. Shenderova A., Burke T.G., and Schwendeman S.P. Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm Res 14 10 (1997) 1406-1414
116. Lutsiak M.E., Robinson D.R., Coester C., Kwon G.S., and Samuel J. Analysis of poly(d,l-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 19 10 (2002) 1480-1487
117. Newman K.D., Elamanchili P., Kwon G.S., and Samuel J. Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 60 3 (2002) 480-486
118. Ishii N., Fukushima J., Kaneko T., Okada E., Tani K., Tanaka S.I., et al. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 13 16 (1997) 1421-1428
119. Ambrosch F., Wiedermann G., Jonas S., Althaus B., Finkel B., Gluck R., et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15 11 (1997) 1209-1213
120. Okamoto T., Kaneda Y., Yuzuki D., Huang S.K., Chi D.D., and Hoon D.S. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine. Gene Ther 4 9 (1997) 969-976
121. Kwak L.W., Pennington R., Boni L., Ochoa A.C., Robb R.J., and Popescu M.C. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J Immunol 160 8 (1998) 3637-3641
122. Alving C.R., and Swartz Jr. G.M. Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Crit Rev Immunol 10 5 (1991) 441-453
123. Sjolander S., Drane D., Davis R., Beezum L., Pearse M., and Cox J. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses. Vaccine 19 28-29 (2001) 4072-4080
124. Sjolander A., Drane D., Maraskovsky E., Scheerlinck J.P., Suhrbier A., Tennent J., et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine 19 17-19 (2001) 2661-2665
125. Watson D.L., Lovgren K., Watson N.A., Fossum C., Morein B., and Hoglund S. Inflammatory response and antigen localization following immunization with influenza virus ISCOMs. Inflammation 13 6 (1989) 641-649
126. Watson D.L., Watson N.A., Fossum C., Lovgren K., and Morein B. Interactions between immune-stimulating complexes (ISCOMs) and peritoneal mononuclear leucocytes. Microbiol Immunol 36 2 (1992) 199-203
127. Maloy K.J., Donachie A.M., and Mowat A.M. Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS. Eur J Immunol 25 10 (1995) 2835-2841
128. Raychaudhuri S., and Rock K.L. Fully mobilizing host defense: building better vaccines. Nat Biotechnol 16 11 (1998) 1025-1031
129. Kovacsovics-Bankowski M., Clark K., Benacerraf B., and Rock K.L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90 (1993) 4942-4946
130. Song R., and Harding C.V. Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. J Immunol 156 11 (1996) 4182-4190
131. Vidard L., Kovacsovics-Bankowski M., Kraeft S.K., Chen L.B., Benacerraf B., and Rock K.L. Analysis of MHC Class II presentation of particulate antigens of B lymphocytes. J Immunol 156 8 (1996) 2809-2818
132. Chen D., Maa Y.F., and Haynes J.R. Needle-free epidermal powder immunization. Expert Rev Vaccines 1 3 (2002) 265-276
133. Larregina A.T., Watkins S.C., Erdos G., Spencer L.A., Storkus W.J., Beer Stolz D., et al. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther 8 8 (2001) 608-617
134. Morel P.A., Falkner D., Plowey J., Larregina A.T., and Falo L.D. DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine 22 3-4 (2004) 447-456
135. Mumper R.J., and Ledebur Jr. H.C. Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization. Mol Biotechnol 19 1 (2001) 79-95
136. Kwon Y.J., James E., Shastri N., and Frechet J.M. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci USA 102 51 (2005) 18264-18268
137. Kwon Y.J., Standley S.M., Goh S.L., and Frechet J.M. Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J Control Release 105 3 (2005) 199-212
138. Streilein J.W., Lonsberry L.W., and Bergstresser P.R. Depletion of epidermal langerhans cells and Ia immunogenicity from tape-stripped mouse skin. J Exp Med 155 3 (1982) 863-871
139. Scharton-Kersten T., Glenn G.M., Vassell R., Yu J., Walwender D., and Alving C.R. Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine 17 Suppl. 2 (1999) S37-S43
140. Tang D.C., Shi Z., and Curiel D.T. Vaccination onto bare skin. Nature 388 6644 (1997) 729-730
141. Kaiserlian D., and Etchart N. Epicutaneous and transcutaneous immunization using DNA or proteins. Eur J Dermatol 9 3 (1999) 169-176
142. Fan H., Lin Q., Morrissey G.R., and Khavari P.A. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 17 9 (1999) 870-872
143. Guebre-Xabier M., Hammond S.A., Ellingsworth L.R., and Glenn G.M. Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J Virol 78 14 (2004) 7610-7618
144. Guerena-Burgueno F., Hall E.R., Taylor D.N., Cassels F.J., Scott D.A., Wolf M.K., et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 70 4 (2002) 1874-1880
145. De Creus A., Van Beneden K., Taghon T., Stolz F., Debacker V., Plum J., et al. Langerhans cells that have matured in vivo in the absence of T cells are fully capable of inducing a helper CD4 as well as a cytotoxic CD8 response. J Immunol 165 2 (2000) 645-653
146. Ghazizadeh S., Kalish R.S., and Taichman L.B. Immune-mediated loss of transgene expression in skin: implications for cutaneous gene therapy. Mol Ther 7 3 (2003) 296-303
147. Guebre-Xabier M., Hammond S.A., Epperson D.E., Yu J., Ellingsworth L., and Glenn G.M. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J Virol 77 9 (2003) 5218-5225
148. Baca-Estrada M.E., Foldvari M., Ewen C., Badea I., and Babiuk L.A. Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine 18 17 (2000) 1847-1854
149. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 5102 (1993) 1745-1749
150. Ulmer J.B., Fu T.M., Deck R.R., Friedman A., Guan L., DeWitt C., et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72 7 (1998) 5648-5653
151. Cho H.J., Takabayashi K., Cheng P.M., Nguyen M.D., Corr M., Tuck S., et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 18 5 (2000) 509-514
152. Cui Z., and Mumper R.J. Topical immunization using nanoengineered genetic vaccines. J Control Release 81 1-2 (2002) 173-184
153. Randolph G.J., Angeli V., and Swartz M.A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5 8 (2005) 617-628
154. Guermonprez P., and Amigorena S. Pathways for antigen cross presentation. Springer Semin Immunopathol 26 3 (2005) 257-271
155. Le Borgne M., Etchart N., Goubier A., Lira S.A., Sirard J.C., van Rooijen N., et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 24 2 (2006) 191-201
156. Lori F., Trocio J., Bakare N., Kelly L.M., and Lisziewicz J. DermaVir, a novel HIV immunisation technology. Vaccine 23 17-18 (2005) 2030-2034
157. Lisziewicz J., Trocio J., Whitman L., Varga G., Xu J., Bakare N., et al. DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol 124 1 (2005) 160-169
158. Altin J.G., van Broekhoven C.L., and Parish C.R. Targeting dendritic cells with antigen-containing liposomes: antitumour immunity. Expert Opin Biol Ther 4 11 (2004) 1735-1747
159. van Broekhoven C.L., Parish C.R., Demangel C., Britton W.J., and Altin J.G. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 64 12 (2004) 4357-4365
160. Hammond S.A., Tsonis C., Sellins K., Rushlow K., Scharton-Kersten T., Colditz I., et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev 43 1 (2000) 45-55
161. Scharton-Kersten T., Yu J., Vassell R., O'Hagan D., Alving C.R., and Glenn G.M. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 68 9 (2000) 5306-5313
162. Glenn G.M., Villar C.P., Flyer D.C., Bourgeois A.L., McKenzie R., Lavker R.M., et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immun 75 5 (2007) 2163-2170
163. McKenzie R., Bourgeois A.L., Frech S.A., Flyer D.C., Bloom A., Kazempour K., et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25 18 (2007) 3684-3691
164. Ennis F.A., Cruz J., Jameson J., Klein M., Burt D., and Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259 2 (1999) 256-261
165. Rimmelzwaan G.F., Nieuwkoop N., Brandenburg A., Sutter G., Beyer W.E., Maher D., et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19 9-10 (2000) 1180-1187
166. Lademann J., Otberg N., Jacobi U., Hoffman R.M., and Blume-Peytavi U. Follicular penetration and targeting. J Invest Dermatol Symp Proc 10 3 (2005) 301-303
167. Toll R., Jacobi U., Richter H., Lademann J., Schaefer H., and Blume-Peytavi U. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J Invest Dermatol 123 1 (2004) 168-176
168. Yagi H., Hashizume H., Horibe T., Yoshinari Y., Hata M., Ohshima A., et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 66 20 (2006) 10136-10144
169. Robinson H.L., and Amara R.R. T cell vaccines for microbial infections. Nat Med 11 4 Suppl. (2005) S25-S32